Related Experiment Video
Updated: Jul 25, 2025
07:53
Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
Published on: April 15, 2022
4.3K
IgE multiple myeloma: detection and follow-up
Beatriz Nafría Jiménez1,2, Raquel Oliveros Conejero1
1Department of Clinical Biochemistry, Hospital Universitario Donostia, San Sebastián, Spain.
Advances in Laboratory Medicine
|June 26, 2023
Summary
Immunoglobulin E (IgE) multiple myeloma is rare. Early detection via protein assays is key for managing this uncommon monoclonal gammopathy, as demonstrated in a recent case study.
Area of Science:
- Hematology
- Oncology
- Clinical Chemistry
Background:
- Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal gammopathy.
- Immunoglobulin E (IgE) multiple myeloma is an extremely rare subtype, accounting for less than 0.1% of all MM cases.
- Accurate detection and quantification of the monoclonal component are essential for diagnosis and management.
Observation:
- A 45-year-old patient presented with elbow pain and was diagnosed with IgE-Kappa multiple myeloma.
- Diagnosis was confirmed through comprehensive laboratory, radiological, and bone marrow evaluations.
- The patient underwent induction chemotherapy followed by hematopoietic stem-cell transplantation and is currently in follow-up.
Findings:
- Protein electrophoresis and immunofixation assays identified an IgE-Kappa monoclonal component.
- This detection preceded the emergence of classic CRAB symptoms (hypercalcemia, renal involvement, anemia, bone pain).
- Early identification of the IgE-Kappa component facilitated prompt therapeutic intervention.
Implications:
- This case highlights the critical role of sensitive protein assays in diagnosing rare forms of multiple myeloma.
- Early detection of IgE-Kappa MM can lead to timely management and potentially improved patient outcomes.
- Understanding the clinical laboratory findings associated with IgE-Kappa MM is crucial for effective disease management.
